Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 11/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.79 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.79 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | NPC1 | O15118 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29788460 | 1.00 | DHODH (0.80) | DHODHKDM4ELMNASMN1; SMN2PDE10A | |
| SCHEMBL29536364 | 0.89 | DHODH (1.00) | DHODHKDM4ELMNASMN1; SMN2PDE10A | |
| SCHEMBL2467110 | 0.89 | DHODH (1.00) | DHODHKDM4ELMNASMN1; SMN2PDE10A | |
| Cinchophen SCHEMBL25519 | 0.89 | KDM4E (1.00) | DHODHKDM4ELMNASMN1; SMN2PDE10A | |
| Cinchophen SCHEMBL7588217 | 0.89 | KDM4E (1.00) | DHODHKDM4ELMNASMN1; SMN2PDE10A | |
| Cinchophen SCHEMBL29376617 | 0.89 | KDM4E (1.00) | DHODHKDM4ELMNASMN1; SMN2PDE10A | |
| SCHEMBL10867811 | 0.88 | DHODH (0.62) | DHODHKDM4ELMNASMN1; SMN2PDE10A | |
| SCHEMBL10436053 | 0.88 | DHODH (0.67) | DHODHKDM4ELMNASMN1; SMN2PDE10A | |
| SCHEMBL19537432 | 0.88 | KDM4E (0.74) | DHODHKDM4ELMNASMN1; SMN2PDE10A | |
| Cinchophen SCHEMBL4464779 | 0.87 | KDM4E (0.97) | DHODHKDM4ELMNASMN1; SMN2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108250230-B | Refining method of diisopropylamine silane | 浙江博瑞电子科技有限公司 | 2020-09-15 | — | — | CN | claimed |
| EP-4617270-A1 | ISOINDOLINONE DERIVATIVE HAVING QUINOLINE AMIDE STRUCTURE, AND USE THEREOF | Oncord Bio Inc (KR) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024101764-A1 | ISOINDOLINONE DERIVATIVE HAVING QUINOLINE AMIDE STRUCTURE, AND USE THEREOF | 주식회사 온코드바이오 | 2024-05-16 | — | — | WO | disclosed |
| CN-111574530-B | ACC inhibitor and medical application thereof | 徐州医科大学 | 2022-07-26 | — | — | CN | disclosed |
| CN-108358838-B | Novel quinoline-substituted Schiff base derivative with biological activity and synthesis method and application thereof | 河南师范大学 | 2021-05-18 | — | — | CN | disclosed |
| CN-108250230-B | Refining method of diisopropylamine silane | 浙江博瑞电子科技有限公司 | 2020-09-15 | — | — | CN | disclosed |
| CN-111574530-A | ACC inhibitor and medical application thereof | 徐州医科大学 | 2020-08-25 | — | — | CN | disclosed |
| CN-108250230-A | A kind of process for purification of diisopropylamine silane | 浙江博瑞电子科技有限公司 | 2018-07-06 | — | — | CN | disclosed |
| EP-2325181-B1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2017-03-29 | — | — | EP | disclosed |
| WO-2016202898-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | WO | disclosed |
| WO-2009082346-A1 | NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009082346-A1 | NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| EP-0726254-B1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS (JP) | 1998-05-06 | — | — | EP | disclosed |
| US-5627193-A | MEDICAL DIAGNOSIS, CARDIOVASCULAR DIAORDERS AND PROTECTION OF ORGANS FOR TRANSPLANTATION | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-05-06 | — | — | US | disclosed |
| EP-0726254-A1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-08-14 | — | — | EP | disclosed |
| US-4711890-A | TREATMENT OF ANXIETY STATES OR OF PULMONARY, RENAL, CIRCULATORY OF CARDIOVASCULAR DISORDERS | RHONE-POULENC SANTE (FR) | 1987-12-08 | — | — | US | disclosed |
| US-4684652-A | TREATING ANXIETY OR CARDIOVASCULAR DISORDERS | RHONE-POULENC SANTE (FR) | 1987-08-04 | — | — | US | disclosed |
| EP-0168812-A1 | 4-Amino-2-phenyl quinolines, methods and intermediates for their preparation and medicaments containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-01-22 | — | — | EP | disclosed |
| US-4560692-A | ANTICONVULSANTS OR ANXIOLYTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-12-24 | — | — | US | disclosed |
| US-4433150-A | HYPNBOTICS, ANTICONVULSANTS, TRANQUILIZERS, ANTIDEPRESSANTS, SEDATIVES, ANTIARRHYTHMIA AGENTS | PHARMINDUSTRIE (FR) | 1984-02-21 | — | — | US | disclosed |